A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus

NCT01648582 · Completed

Last updated 2026-05-28

This study compared how well dulaglutide and insulin glargine lower blood sugar levels over 26 weeks in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 774 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-07 · est. completion 2014-12

Where 30 sites · China, Mexico, Russia, South Korea

What this study is testing ClinicalTrials.gov NCT01648582 ↗

Description as written by the study sponsor.

The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.

Treatments tested

Dulaglutide also known as LY2189265 Drug

Administered SC
Insulin glargine Drug

Administered SC per dosing titration schedule
Metformin Drug

Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Sulfonylureas Drug

Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.

Main thing measured	Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
Sponsor	Eli Lilly and Company
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01648582 ↗